Please login to the form below
norovirus
This page shows the latest norovirus news and features for those working in and with pharma, biotech and healthcare.
Takeda starts trial of norovirus vaccine
There is no drug treatment available, so management of norovirus focuses on preventing transmission and supportive care for those infected. ... It includes antigens from norovirus genotypes GI.1 and GII.4, which are thought to cause the majority of human
Latest news
-
Germinating virologists
The aim is to exploit the expertise he has built up in generating Naked Scientist to increase public knowledge in microbiology on issues such as C difficile, norovirus and MRSA.
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest Intelligence
-
Pharma deals during October 2012
LigoCyte has a number of vaccine products in development, including its lead candidate, which is in phase I/II vaccine to prevent norovirus gastroenteritis, commonly known as winter vomiting disease.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Takeda appoints head of vaccines development
Boslego will be responsible for accelerating global vaccine development activities with a focus on lead development programmes for dengue, norovirus and seasonal influenza.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
How will the events and exhibitions industry change post-Coronavirus?
However some practices will become the norm. For many years cruise ships have had hand sanitisers sited around ships to protect passengers from Norovirus, which is an ever-present threat.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Gilead agrees $21bn buyout of Immunomedics
- New medical communications agency BOLDSCIENCE launches
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- BMS eyes approval for second Opdivo combo in kidney cancer
- Moderna inks R&D agreements with Vertex and Chiesi
- FDA hands BMS and bluebird bio a priority review for ide-cel
- Janssen’s EGFR-targeting treatment regimen shows early benefit in lung cancer
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- Could formulary intelligence be your brand differentiator?
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Porterhouse Medical strengthens its senior management team
PMHub
Aptus Health
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...
Latest intelligence
- Could formulary intelligence be your brand differentiator?
- Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
- Improve clinical trials through patient journey mapping
- Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
Quick links
Infographics
